May 7, 2018 09:17 AM EDTUpdated May 26, 08:50 PM
Pharma
Cell/Gene Tx

Is bio­phar­ma’s first $1.5M ther­a­py now in Phase III?

John Carroll

Editor & Founder

Key­ing off of Spark Ther­a­peu­tics’ roll­out of Lux­tur­na as the first ap­proved gene ther­a­py in the US, the an­a­lysts at Leerink have been crunch­ing the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Every FDA drug ap­proval from 2024: Few­er nods, but long-await­ed treat­ments cross the fin­ish line

Ex­clu­sive: Joe Jimenez's Adi­tum Bio rings in new year with $428M third fund

FDA of­fers suite of new guid­ance on AI, ac­cel­er­at­ed ap­provals, clin­i­cal tri­als and more

WuXi Bi­o­log­ics to sell Irish vac­cine site to Mer­ck for $500M

I-Mab stops work on CD73; Citius to pur­sue ‘strate­gic’ op­tions

Ex­clu­sive: AI biotech Iambic snags CFO who helped steer Re­cur­sion-Ex­sci­en­tia deal

A service from the Financial Times